Trial Outcomes & Findings for Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia (NCT NCT01184014)

NCT ID: NCT01184014

Last Updated: 2018-06-13

Results Overview

Starting 3 hours after the initial index blood glucose (BG) \>180 measure, across the entire hospital stay or up through 5 days if hospital length of stay (LOS) is \> 5 days

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

72 participants

Primary outcome timeframe

starting 3 hours after the initial index BG>180 measure, across the entire hospital stay or up through 5 days if hospital LOS is > 5 days

Results posted on

2018-06-13

Participant Flow

Recruitment from May 2011 to August 2012. Location: Hospital.

Participant milestones

Participant milestones
Measure
Experimental Group
a study-specific steroid NPH dosing algorithm plus standard recommended care
Control Group
the standard recommended care (Methodist Hospital Complete Insulin Orders)
Overall Study
STARTED
35
37
Overall Study
COMPLETED
30
31
Overall Study
NOT COMPLETED
5
6

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Experimental Group
n=35 Participants
a study-specific steroid NPH dosing algorithm plus standard recommended care
Control Group
n=37 Participants
the standard recommended care (Methodist Hospital Complete Insulin Orders)
Total
n=72 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
14 Participants
n=5 Participants
18 Participants
n=7 Participants
32 Participants
n=5 Participants
Age, Categorical
>=65 years
21 Participants
n=5 Participants
19 Participants
n=7 Participants
40 Participants
n=5 Participants
Age, Continuous
67.1 years
STANDARD_DEVIATION 14.2 • n=5 Participants
71.6 years
STANDARD_DEVIATION 44.6 • n=7 Participants
69.4 years
STANDARD_DEVIATION 33.1 • n=5 Participants
Sex: Female, Male
Female
21 Participants
n=5 Participants
24 Participants
n=7 Participants
45 Participants
n=5 Participants
Sex: Female, Male
Male
14 Participants
n=5 Participants
13 Participants
n=7 Participants
27 Participants
n=5 Participants
Region of Enrollment
United States
35 participants
n=5 Participants
37 participants
n=7 Participants
72 participants
n=5 Participants

PRIMARY outcome

Timeframe: starting 3 hours after the initial index BG>180 measure, across the entire hospital stay or up through 5 days if hospital LOS is > 5 days

Starting 3 hours after the initial index blood glucose (BG) \>180 measure, across the entire hospital stay or up through 5 days if hospital length of stay (LOS) is \> 5 days

Outcome measures

Outcome measures
Measure
Experimental Group
n=30 Participants
a study-specific steroid (NPH) dosing algorithm plus standard recommended care. The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO). NPH insulin plus Complete Insulin Orders: NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
Control Group
n=31 Participants
the standard recommended care (Methodist Hospital Complete Insulin Orders) Complete Insulin Orders: 3-part insulin which includes background, meal-time and correction factor
Mean Blood Glucose of All Readings
157.2 mg/dL
Standard Deviation 6.1
181.8 mg/dL
Standard Deviation 32.6

Adverse Events

Experimental Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Richard Bergenstal

International Diabetes Center

Phone: 952-993-3796

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place